NATIONAL HARBOR, MD. – Menopause is often accompanied by complex changes in sexual health and function, and factors contributing to low libido and other sexual problems in postmenopausal women may...
NATIONAL HARBOR, MD. – Treating menopause symptoms in women who still have a uterus can be difficult, but alternatives to estrogen are available.
For many women, the use of estrogen therapies is...
PHILADELPHIA – Every recurrence of Clostridium difficile was associated with a hospital admission in 1 in 4 cases and a complication in 1 in 15 cases, according to a retrospective Canadian...
AMSTERDAM – The investigational biologic agent secukinumab continued to show strong efficacy through 52 weeks of treatment in a new secondary analysis of the pivotal phase III ERASURE trial.
For...
AMSTERDAM – Does pushing for a PASI 90 response instead of settling for a PASI 75 matter to patients being treated for moderate-to-severe chronic plaque psoriasis?
You bet it does, Dr. Mark G....
AMSTERDAM – Does pushing for a PASI 90 response instead of settling for a PASI 75 matter to patients being treated for moderate-to-severe chronic plaque psoriasis?
You bet it does, Dr. Mark G....
NATIONAL HARBOR, MD. – Does the Food and Drug Administration’s black-box warning on estrogen contribute to noncompliance – or worse, to clinicians being unwilling to prescribe estrogen treatments –...
The Food and Drug Administration has approved new labeling for the opioid analgesic Embeda to include information about the drug’s abuse-preventive properties, the agency announced Oct. 17.
The...
Rheumatoid arthritis patients treated with the biologic tocilizumab and the Janus kinase inhibitor tofacitinib had significant changes to their lipid levels in a meta-analysis of randomized,...